The intervention being tested is BNT327, administered in two dose levels, combined with standard chemotherapy drugs such as etoposide, carboplatin, paclitaxel, and topotecan. The purpose is to ...

BNT327/PM8002 has shown encouraging efficacy and tolerability in patients across various tumor types, with more than 700 patients treated in clinical trials to date.

BNT327, BioNTech’ s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech, which acquired BNT327 in an $800 million acquisition of China-based biotech Biotheus late last year, has advanced the drug into Phase 3 trials in both small cell and non-small cell lung ...

BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to ...

BioNTech SE is currently sponsoring a clinical study titled ‘A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With ...

BioNTech's BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date.

BioNTech's BNT327 could lead U.S. and European approvals for key cancers, with pivotal data expected in 2025. Ready to turn the market’s comeback into steady cash flow?

Doctors are looking for ways to improve treatment for NSCLC. In this trial, they are looking at an experimental drug called BNT327. It is a new type of immunotherapy drug . It works in 2 ways. It aims ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech SE and Bristol Myers Squibb announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific ...